221 related articles for article (PubMed ID: 8262670)
1. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
Plumb JA; Workman P
Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
[TBL] [Abstract][Full Text] [Related]
2. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.
Plumb JA; Gerritsen M; Workman P
Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885
[TBL] [Abstract][Full Text] [Related]
3. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas.
Walton MI; Bibby MC; Double JA; Plumb JA; Workman P
Eur J Cancer; 1992; 28A(10):1597-600. PubMed ID: 1389472
[TBL] [Abstract][Full Text] [Related]
4. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022
[TBL] [Abstract][Full Text] [Related]
5. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
6. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
Walton MI; Sugget N; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):643-7. PubMed ID: 1544831
[TBL] [Abstract][Full Text] [Related]
7. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.
Bailey SM; Wyatt MD; Friedlos F; Hartley JA; Knox RJ; Lewis AD; Workman P
Br J Cancer; 1997; 76(12):1596-603. PubMed ID: 9413948
[TBL] [Abstract][Full Text] [Related]
8. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
Walton MI; Smith PJ; Workman P
Cancer Commun; 1991 Jul; 3(7):199-206. PubMed ID: 1714284
[TBL] [Abstract][Full Text] [Related]
9. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.
Collard J; Matthew AM; Double JA; Bibby MC
Br J Cancer; 1995 Jun; 71(6):1199-203. PubMed ID: 7779711
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia.
Robertson N; Haigh A; Adams GE; Stratford IJ
Eur J Cancer; 1994; 30A(7):1013-9. PubMed ID: 7946565
[TBL] [Abstract][Full Text] [Related]
11. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.
Doherty GP; Leith MK; Wang X; Curphey TJ; Begleiter A
Br J Cancer; 1998 Apr; 77(8):1241-52. PubMed ID: 9579829
[TBL] [Abstract][Full Text] [Related]
12. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
[TBL] [Abstract][Full Text] [Related]
13. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.
Maliepaard M; Wolfs A; Groot SE; de Mol NJ; Janssen LH
Br J Cancer; 1995 Apr; 71(4):836-9. PubMed ID: 7536024
[TBL] [Abstract][Full Text] [Related]
14. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
15. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
Smitskamp-Wilms E; Hendriks HR; Peters GJ
Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
[TBL] [Abstract][Full Text] [Related]
16. Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites.
Bailey SM; Lewis AD; Knox RJ; Patterson LH; Fisher GR; Workman P
Biochem Pharmacol; 1998 Sep; 56(5):613-21. PubMed ID: 9783730
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
Bailey SM; Suggett N; Walton MI; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression.
Smitskamp-Wilms E; Peters GJ; Pinedo HM; van Ark-Otte J; Giaccone G
Biochem Pharmacol; 1994 Apr; 47(8):1325-32. PubMed ID: 7514407
[TBL] [Abstract][Full Text] [Related]
19. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
Smitskamp-Wilms E; Giaccone G; Pinedo HM; van der Laan BF; Peters GJ
Br J Cancer; 1995 Oct; 72(4):917-21. PubMed ID: 7547240
[TBL] [Abstract][Full Text] [Related]
20. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
Sharp SY; Kelland LR; Valenti MR; Brunton LA; Hobbs S; Workman P
Mol Pharmacol; 2000 Nov; 58(5):1146-55. PubMed ID: 11040064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
